Viracta Therapeutics (NASDAQ:VIRX) just reported results for the second quarter of 2024.
- Viracta Therapeutics reported earnings per share of -25 cents. This was above the analyst estimate for EPS of -37 cents.
- The company did not report any revenue for the quarter.